iSpecimen Inc (ISPC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, iSpecimen Inc (ISPC) has a cash flow conversion efficiency ratio of -4.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.36 Million) by net assets ($814.04K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See iSpecimen Inc balance sheet quality to measure how much of total assets are equity-financed.
iSpecimen Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how iSpecimen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow reinvestment rate of iSpecimen Inc to assess the company's total reinvestment commitment from operating cash flow.
iSpecimen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iSpecimen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baillie Gifford UK Growth Fund PLC
LSE:BGUK
|
0.006x |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
-0.069x |
|
Nickel North Exploration Corp
V:NNX
|
0.018x |
|
Schroder UK Mid Cap Fund PLC
LSE:SCP
|
0.003x |
|
Photocat AS
ST:PCAT
|
0.042x |
|
Psyence Biomedical Ltd. Common Shares
NASDAQ:PBM
|
0.000x |
|
Birddog Technology Ltd
AU:BDT
|
-0.302x |
|
Ordissimo
PA:ALORD
|
0.088x |
Annual Cash Flow Conversion Efficiency for iSpecimen Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of iSpecimen Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ISPC market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.09 Million | $-4.24 Million | -1.373x | +44.98% |
| 2024-12-31 | $3.31 Million | $-8.26 Million | -2.496x | -318.63% |
| 2023-12-31 | $9.74 Million | $-5.81 Million | -0.596x | -108.13% |
| 2022-12-31 | $20.31 Million | $-5.82 Million | -0.286x | +20.01% |
| 2021-12-31 | $29.79 Million | $-10.67 Million | -0.358x | -3487.29% |
| 2020-12-31 | $-27.28 Million | $-288.38K | 0.011x | -91.04% |
| 2019-12-31 | $-22.72 Million | $-2.68 Million | 0.118x | -18.96% |
| 2018-12-31 | $-18.42 Million | $-2.68 Million | 0.146x | -- |
About iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have ac… Read more